Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
Sundar Ramalingam(Emory University), Thanyanan Reungwetwattana(Mahidol University), B. Chewaskulyong(Chiang Mai University), Arunee Dechaphunkul(Prince of Songkla University), K.H. Lee(Chungbuk National University Hospital), Fumio Imamura(Osaka International Cancer Institute), Naoyuki Nogami(Shikoku Cancer Center), Yuichiro Ohe(Tokyo National Hospital), Ying Cheng(Jilin Province Tumor Hospital), Byoung Chul Cho(Yonsei University), E.K. Cho(Gachon University Gil Medical Center), Johan Vansteenkiste(KU Leuven), P.J. Voon(Sarawak General Hospital), Chao Zhou(Tongji University), Jhanelle E. Gray(Moffitt Cancer Center), Rachel Hodge(AstraZeneca (United Kingdom)), Yuri Rukazenkov(AstraZeneca (United Kingdom)), J.C. Soria(Institut Gustave Roussy)
Cited by 34Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis